I’m watching the Tecfidera launch, of course, but this is pretty far down on my list of concerns as a MNTA shareholder. If MNTA gets FDA approval for generic Copaxone, it will be one of the largest-selling US generic drugs ever, regardless of what Tecfidera does. (See the previous post.)
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”